ANL vs. ELVN, SAVA, ARCT, IRWD, INVA, LQDA, VRNA, GYRE, ARQT, and OPK
Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Enliven Therapeutics (ELVN), Cassava Sciences (SAVA), Arcturus Therapeutics (ARCT), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Liquidia (LQDA), Verona Pharma (VRNA), Gyre Therapeutics (GYRE), Arcutis Biotherapeutics (ARQT), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Enliven Therapeutics (NASDAQ:ELVN) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
Enliven Therapeutics currently has a consensus price target of $34.00, indicating a potential upside of 62.37%. Adlai Nortye has a consensus price target of $30.00, indicating a potential upside of 708.63%. Given Enliven Therapeutics' higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Enliven Therapeutics.
Enliven Therapeutics and Adlai Nortye both received 4 outperform votes by MarketBeat users.
Enliven Therapeutics' return on equity of 0.00% beat Adlai Nortye's return on equity.
In the previous week, Enliven Therapeutics had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Enliven Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.89 beat Enliven Therapeutics' score of 0.59 indicating that Enliven Therapeutics is being referred to more favorably in the media.
95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Enliven Therapeutics beats Adlai Nortye on 4 of the 7 factors compared between the two stocks.
Get Adlai Nortye News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adlai Nortye Competitors List
Related Companies and Tools
